Somagenetix, a Zurich-based biotech company founded in 2019, has raised 10 million Swiss francs in a Series A financing round led by Vi Partners, with participation from Schroders Capital, Zürcher Kantonalbank, and Verve Ventures. The funds will advance their gene therapy SGX-001 for chronic granulomatous disease (CGD) into clinical trials, aiming to provide an alternative to limited stem cell transplants. CEO Andrin Oswald and co-founder Janine Reichenbach emphasize the potential of their innovative lentiviral gene therapy platform to transform treatment for phagocyte-related diseases.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
